Immunotherapy, avelumab and protecting the immunocompromised


This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “The avelumab story and what it means for urothelial carcinoma”, and “Immunocompromised are ‘forgotten’ when it comes to viral protection”.

In the first article, you will hear from Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences.

In the second article, Lu Rahman speaks to Dr Stuart Hill, Medical Director for Merck, about the development of the avelumab and what this means for the treatment of bladder cancer.

In the third article, Dr. Jeffery Stein, CEO of Cidara and an expert in viral diseases, talks about the drug-Fc conjugate (DFCs), a new class of immunotherapeutic antivirals.

You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Listen here: 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free